Gemifloxacin mesylate Clinical Trials

• Imatinib Mesylate in Treating Patients With Gliomas
  ClinicalTrials.gov Identifier: NCT00039364 - Active, not recruiting
  adult brain tumor
  
• Study of STA-5326 Mesylate in Patients with Moderate to Severe Crohn''s Disease.
  ClinicalTrials.gov Identifier: NCT00138840 - Active, not recruiting
  Crohn''s disease
  
• Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00363649 - Recruiting
  Leukemia
  
• Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
  ClinicalTrials.gov Identifier: NCT00510354 - Recruiting
  Progressive Gastrointestinal Stromal Tumor
  
• Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00003008 - Active, not recruiting
  epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma
  
• AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
  ClinicalTrials.gov Identifier: NCT00146913 - Active, not recruiting
  Chronic Myeloid Leukemia
  
• Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
  ClinicalTrials.gov Identifier: NCT00025246 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery
  ClinicalTrials.gov Identifier: NCT00041197 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Phase II Study of Hyper-CVAD plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00038610 - Active, not recruiting
  Leukemia, Lymphocytic, Acute, L2
  
• Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00091078 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
  ClinicalTrials.gov Identifier: NCT00062205 - Active, not recruiting
  recurrent tumors of the Ewing's family
  
• Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
  ClinicalTrials.gov Identifier: NCT00055939 - Active, not recruiting
  previously treated childhood rhabdomyosarcoma; recurrent childhood rhabdomyosarcoma
  
• Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
  ClinicalTrials.gov Identifier: NCT00055952 - Active, not recruiting
  Ewing's family of tumors; childhood soft tissue sarcoma
  
• BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
  ClinicalTrials.gov Identifier: NCT00112775 - Active, not recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia; relapsing chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00090987 - Active, not recruiting
  epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma
  
• Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma
  ClinicalTrials.gov Identifier: NCT00075400 - Active, not recruiting
  uterine carcinosarcoma; recurrent uterine sarcoma
  
• Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00028002 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/neu-Expressing Cancer
  ClinicalTrials.gov Identifier: NCT00084513 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00087152 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00041041 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00041236 - Active, not recruiting
  adult soft tissue sarcoma; uterine leiomyosarcoma; uterine sarcoma
  
• Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
  ClinicalTrials.gov Identifier: NCT00264160 - Recruiting
  Chronic Mylogenous Leukemia (CML) Patients Resistant or Intolerant to Imatinib Mesylate Therapy
  
• Imatinib Mesylate in Treating Patients With Myelofibrosis
  ClinicalTrials.gov Identifier: NCT00039416 - Active, not recruiting
  Polycythemia Vera; chronic idiopathic myelofibrosis; Essential Thrombocythemia; Chronic Myelomonocytic Leukemia
  
• Imatinib Mesylate in Treating Patients With Myelofibrosis
  ClinicalTrials.gov Identifier: NCT00245128 - Active, not recruiting
  Chronic Myeloproliferative Disorders
  
• Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
  ClinicalTrials.gov Identifier: NCT00044304 - Recruiting
  Hypereosinophilic Syndrome
  
• Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
  ClinicalTrials.gov Identifier: NCT00080678 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer; bone metastases
  
• Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00103168 - Recruiting
  gastrointestinal stromal tumor
  
• Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00028847 - Active, not recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
  ClinicalTrials.gov Identifier: NCT00030667 - Active, not recruiting
  Ewing's family of tumors; childhood soft tissue sarcoma; Gastrointestinal Cancer; metastatic cancer; Neuroblastoma; Osteosarcoma
  
• AG-858 and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Were Previously Treated With Imatinib Mesylate
  ClinicalTrials.gov Identifier: NCT00070395 - Recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00023972 - Active, not recruiting
  stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00112632 - Recruiting
  gastrointestinal stromal tumor
  
• Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00052494 - Active, not recruiting
  extensive stage small cell lung cancer; Recurrent Small Cell Lung Cancer
  
• Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00080665 - Active, not recruiting
  Male Breast Cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; recurrent breast cancer
  
• Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00053248 - Active, not recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
  ClinicalTrials.gov Identifier: NCT00085475 - Active, not recruiting
  recurrent adult soft tissue sarcoma; stage III adult soft tissue sarcoma; stage IV adult soft tissue sarcoma; adult fibrosarcoma; ...
  
• Oblimersen Plus Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00049192 - Active, not recruiting
  Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Refractory Metastatic and/or Unresectable Stomach or Gastroesophageal Junction Cancer
  ClinicalTrials.gov Identifier: NCT00068380 - Active, not recruiting
  recurrent gastric cancer; stage IV gastric cancer; recurrent esophageal cancer; stage IV esophageal cancer; stage III esophageal cancer; ...
  
• Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (DFSP) or Transformed Fibrosarcomatous DFSP
  ClinicalTrials.gov Identifier: NCT00084630 - Active, not recruiting
  adult fibrosarcoma; recurrent adult soft tissue sarcoma; stage III adult soft tissue sarcoma; adult malignant fibrous histiocytoma; ...
  
• Interferon alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00045422 - Active, not recruiting
  Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; childhood chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
  ClinicalTrials.gov Identifier: NCT00045669 - Active, not recruiting
  recurrent salivary gland cancer; salivary gland adenoid cystic carcinoma; stage III salivary gland cancer; stage IV salivary gland cancer
  
• Open-Label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
  ClinicalTrials.gov Identifier: NCT00171938 - Active, not recruiting
  Glioblastoma
  
• Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia
  ClinicalTrials.gov Identifier: NCT00116129 - Active, not recruiting
  Fibromyalgia
  
• Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00036751 - Active, not recruiting
  stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00248482 - Active, not recruiting
  Lung Cancer
  
• Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00301093 - Active, not recruiting
  Leukemia
  
• Imatinib Mesylate in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00324636 - Active, not recruiting
  Leukemia
  
• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn’s Disease
  ClinicalTrials.gov Identifier: NCT00234741 - Active, not recruiting
  Crohn’s Disease
  
• Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00359892 - Active, not recruiting
  Hodgkin's Lymphoma
  
• A Multicenter Study to Determine the Effectiveness, Tolerability and Safety Using Two Doses of Study Medication (Rasagiline Mesylate) in Early Parkinson’s Disease Patients Not Treated With Levodopa
  ClinicalTrials.gov Identifier: NCT00203060 - Active, not recruiting
  Parkinson's Disease
  
• A Study to Compare Two Different Anti-HIV Drug Regimens
  ClinicalTrials.gov Identifier: NCT00000924 - Active, not recruiting
  HIV Infections
  
• Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
  ClinicalTrials.gov Identifier: NCT00021229 - Active, not recruiting
  childhood central nervous system germ cell tumor; high-grade childhood cerebral astrocytoma; untreated childhood brain stem glioma; ...
  
• Imatinib Mesylate, Busulfan, Fludarabine, and ATG for CML Patients
  ClinicalTrials.gov Identifier: NCT00499889 - Recruiting
  Leukemia
  
• Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
  ClinicalTrials.gov Identifier: NCT00233948 - Recruiting
  Sarcoma
  
• Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
  ClinicalTrials.gov Identifier: NCT00287846 - Recruiting
  Desmoid Tumor
  
• Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
  ClinicalTrials.gov Identifier: NCT00171977 - Active, not recruiting
  Gastrointestinal Stromal Tumors
  
• Treatment with Combinations of Several Antiviral Drugs in Infants and Young Children with HIV Infection
  ClinicalTrials.gov Identifier: NCT00000872 - Active, not recruiting
  HIV Infections
  
• A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients between Ages 4 and 22 with 7 Drugs, Some at Higher than Usual Doses
  ClinicalTrials.gov Identifier: NCT00001108 - Active, not recruiting
  HIV Infections
  
• Phase I Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With AICP
  ClinicalTrials.gov Identifier: NCT00424385 - Recruiting
  Prostate Cancer
  
• Obatoclax Mesylate, Fludarabine and Rituximab in Previously Treated Patients With B-CLL
  ClinicalTrials.gov Identifier: NCT00574938 - Recruiting
  Chronic Lymphocytic Leukemia
  
• SU011248 in Patients with Malignant Gastrointestinal Stromal Tumor (GIST) That Have Progressed During or Not Tolerated Treatment with Imatinib Mesylate (GLEEVEC™)
  ClinicalTrials.gov Identifier: NCT00075218 - Active, not recruiting
  Gastrointestinal Neoplasms
  
• A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children with Prior Treatment
  ClinicalTrials.gov Identifier: NCT00000902 - Active, not recruiting
  HIV Infections
  
• An Extension Study of the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis
  ClinicalTrials.gov Identifier: NCT00171158 - Active, not recruiting
  Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis
  
• Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
  ClinicalTrials.gov Identifier: NCT00354068 - Recruiting
  Brain and Central Nervous System Tumors
  
• Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
  ClinicalTrials.gov Identifier: NCT00500188 - Recruiting
  Gastrointestinal Stromal Tumors
  
• A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children
  ClinicalTrials.gov Identifier: NCT00000913 - Active, not recruiting
  HIV Infections
  
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
  ClinicalTrials.gov Identifier: NCT00354913 - Recruiting
  Brain and Central Nervous System Tumors
  
• An Extension Study of the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia
  ClinicalTrials.gov Identifier: NCT00171223 - Active, not recruiting
  Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
  
• An Extension Study of the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia
  ClinicalTrials.gov Identifier: NCT00171249 - Active, not recruiting
  Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
  
• Effectiveness of Treating HIV-Positive Patients with an HIV Vaccine (Remune)
  ClinicalTrials.gov Identifier: NCT00005002 - Active, not recruiting
  HIV Infections
  
• Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
  ClinicalTrials.gov Identifier: NCT00290771 - Active, not recruiting
  Recurrent Glioblastoma Multiforme (GBM)
  
• Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
  ClinicalTrials.gov Identifier: NCT00292149 - Active, not recruiting
  Recurrent Glioblastoma Multiforme (GBM)
  
• Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
  ClinicalTrials.gov Identifier: NCT00401024 - Recruiting
  Brain and Central Nervous System Tumors
  
• CCI-779 and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00101088 - Recruiting
  accelerated phase chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; ...
  
• Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
  ClinicalTrials.gov Identifier: NCT00049127 - Recruiting
  adult anaplastic oligodendroglioma; recurrent adult brain tumor; Mixed Gliomas; Adult Oligodendroglioma
  
• Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
  ClinicalTrials.gov Identifier: NCT00008554 - Active, not recruiting
  HIV Infections
  
• Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00070499 - Recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
  ClinicalTrials.gov Identifier: NCT00390897 - Active, not recruiting
  Chronic Myeloid Leukaemia
  
• Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
  ClinicalTrials.gov Identifier: NCT00387933 - Recruiting
  Brain and Central Nervous System Tumors
  
• Treatment with Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
  ClinicalTrials.gov Identifier: NCT00005000 - Active, not recruiting
  HIV Infections
  
• Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination with Nelfinavir in HIV-Positive Children
  ClinicalTrials.gov Identifier: NCT00000893 - Active, not recruiting
  HIV Infections
  
• Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
  ClinicalTrials.gov Identifier: NCT00039377 - Recruiting
  adult acute lymphoblastic leukemia in remission
  
• Trial of Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients
  ClinicalTrials.gov Identifier: NCT00402766 - Recruiting
  Mesothelioma
  
• Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00268229 - Recruiting
  Leukemia
  
• Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
  ClinicalTrials.gov Identifier: NCT00360035 - Recruiting
  Myelofibrosis
  
• Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients with Mild to Moderate Alzheimer's Disease (AD)
  ClinicalTrials.gov Identifier: NCT00104273 - Active, not recruiting
  Dementia, Alzheimer Type
  
• Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
  ClinicalTrials.gov Identifier: NCT00509093 - Recruiting
  Leukemia
  
• A Randomized Trial of the Efficacy and Safety of a Strategy of Starting with Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals with CD4+ Cell Counts Less than or Equal to 200/mm3
  ClinicalTrials.gov Identifier: NCT00000859 - Active, not recruiting
  HIV Infections
  
• PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
  ClinicalTrials.gov Identifier: NCT00335868 - Recruiting
  Leukemia
  
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
  ClinicalTrials.gov Identifier: NCT00171912 - Recruiting
  Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
  
• Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children
  ClinicalTrials.gov Identifier: NCT00002219 - Active, not recruiting
  HIV Infections
  
• Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly with Imatinib Mesylate (STI571) and Chemotherapy.
  ClinicalTrials.gov Identifier: NCT00149136 - Active, not recruiting
  Acute Lymphocytic Leukemia
  
• Combination Chemotherapy With or Without Imatinib Mesylate and/or Peripheral Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
  ClinicalTrials.gov Identifier: NCT00458848 - Recruiting
  Leukemia
  
• Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
  ClinicalTrials.gov Identifier: NCT00074308 - Recruiting
  stage III melanoma; Stage IV Melanoma; Recurrent Melanoma; unspecified adult solid tumor, protocol specific
  
• Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00483366 - Recruiting
  Unspecified Adult Solid Tumor, Protocol Specific
  
• A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given with Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
  ClinicalTrials.gov Identifier: NCT00000887 - Active, not recruiting
  HIV Infections; Pregnancy
  
• Imatinib Mesylate, Bevacizumab, and Cyclophosphamide in Treating Patients With Refractory Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00390156 - Recruiting
  Unspecified Adult Solid Tumor, Protocol Specific
  
• Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00009906 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Comparison of GW433908/Ritonavir to Nelfinavir When Used with Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
  ClinicalTrials.gov Identifier: NCT00009061 - Active, not recruiting
  HIV Infections
  
• Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00258271 - Recruiting
  Leukemia